Tranilast Inhibits Pulmonary Fibrosis by Suppressing TGFβ/SMAD2 Pathway.

Motoyasu KatoFumiyuki TakahashiTadashi SatoYoichiro MitsuishiKen TajimaHiroaki Ihara Fariz NurwidyaHario BaskoroAkiko MurakamiIsao KobayashiMoulid HidayatNaoko ShimadaShinichi SasakiReiko MinekiTsutomu FujimuraToshio KumasakaShin-Ichiro NiwaKazuhisa Takahashi

Published in: Drug design, development and therapy (2020)

These findings suggest that tranilast inhibits pulmonary fibrosis by suppressing TGFβ/SMAD2-mediated ECM protein production, presenting tranilast as a promising and novel anti-fibrotic agent for the treatment of IPF.

Keyphrases

pulmonary fibrosis
transforming growth factor
epithelial mesenchymal transition
idiopathic pulmonary fibrosis
systemic sclerosis
case report
extracellular matrix
binding protein
signaling pathway
protein protein